These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 9819796)

  • 41. Phase I trial of high-dose bolus interleukin-2 and interferon alfa-2a in patients with metastatic malignancy.
    Budd GT; Murthy S; Finke J; Sergi J; Gibson V; Medendorp S; Barna B; Boyett J; Bukowski RM
    J Clin Oncol; 1992 May; 10(5):804-9. PubMed ID: 1569452
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Daily alternating administration of high-dose alpha-2b-interferon and interleukin-2 bolus infusion in metastatic renal cell cancer. A phase II study.
    Bergmann L; Fenchel K; Weidmann E; Enzinger HM; Jahn B; Jonas D; Mitrou PS
    Cancer; 1993 Sep; 72(5):1733-42. PubMed ID: 8348502
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Pilot study of interleukin-2 and lymphokine-activated killer cells combined with immunomodulatory doses of chemotherapy and sequenced with interferon alfa-2a in patients with metastatic melanoma and renal cell carcinoma.
    Sznol M; Clark JW; Smith JW; Steis RG; Urba WJ; Rubinstein LV; VanderMolen LA; Janik J; Sharfman WH; Fenton RG
    J Natl Cancer Inst; 1992 Jun; 84(12):929-37. PubMed ID: 1629914
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Clinical and immune modulatory effects of alternative weekly interleukin-2 and interferon alfa-2a in patients with advanced renal cell carcinoma and melanoma.
    Pichert G; Jost LM; Fierz W; Stahel RA
    Br J Cancer; 1991 Feb; 63(2):287-92. PubMed ID: 1997108
    [TBL] [Abstract][Full Text] [Related]  

  • 45. A randomized phase 2 trial of bevacizumab with or without daily low-dose interferon alfa-2b in metastatic malignant melanoma.
    Varker KA; Biber JE; Kefauver C; Jensen R; Lehman A; Young D; Wu H; Lesinski GB; Kendra K; Chen HX; Walker MJ; Carson WE
    Ann Surg Oncol; 2007 Aug; 14(8):2367-76. PubMed ID: 17534686
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Phase I/II open-label study of the biologic effects of the interleukin-2 immunocytokine EMD 273063 (hu14.18-IL2) in patients with metastatic malignant melanoma.
    Ribas A; Kirkwood JM; Atkins MB; Whiteside TL; Gooding W; Kovar A; Gillies SD; Kashala O; Morse MA
    J Transl Med; 2009 Jul; 7():68. PubMed ID: 19640287
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Safety and efficacy of the antiganglioside GD3 antibody ecromeximab (KW2871) combined with high-dose interferon-α2b in patients with metastatic melanoma.
    Tarhini AA; Moschos SJ; Lin Y; Lin HM; Sander C; Yin Y; Venhaus R; Gajewski TF; Kirkwood JM
    Melanoma Res; 2017 Aug; 27(4):342-350. PubMed ID: 28489678
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Clinical experience with the combined use of recombinant interleukin-2 (IL2) and interferon alfa-2a (IFN alpha) in metastatic melanoma.
    Kruit WH; Goey SH; Monson JR; Stahel RA; Calabresi F; Mertelsmann R; Holdener EE; Eggermont AM; Bolhuis RL; de Mulder PH
    Br J Haematol; 1991 Oct; 79 Suppl 1():84-6. PubMed ID: 1931717
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Results of two sequential phase II studies of interleukin-2 (IL2) in metastatic renal cell carcinoma and melanoma: high-dose continuous intravenous IL2 infusion and subcutaneous IL2 administration in combination with alpha interferon.
    Hidalgo OF; Aramendía JM; Alonso G; Foncillas JG; Brugarolas A
    Rev Med Univ Navarra; 1996; 40(3):6-12. PubMed ID: 9499820
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Phase II trial of interleukin 2, interferon alpha, and 5-fluorouracil in metastatic renal cell cancer: a cytokine working group study.
    Dutcher JP; Logan T; Gordon M; Sosman J; Weiss G; Margolin K; Plasse T; Mier J; Lotze M; Clark J; Atkins M
    Clin Cancer Res; 2000 Sep; 6(9):3442-50. PubMed ID: 10999727
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Dacarbazine and interferon alpha with or without interleukin 2 in metastatic melanoma: a randomized phase III multicentre trial of the Dermatologic Cooperative Oncology Group (DeCOG).
    Hauschild A; Garbe C; Stolz W; Ellwanger U; Seiter S; Dummer R; Ugurel S; Sebastian G; Nashan D; Linse R; Achtelik W; Mohr P; Kaufmann R; Fey M; Ulrich J; Tilgen W
    Br J Cancer; 2001 Apr; 84(8):1036-42. PubMed ID: 11308250
    [TBL] [Abstract][Full Text] [Related]  

  • 52. A phase II trial of concomitant human interleukin-2 and interferon-alpha-2a in patients with disseminated malignant melanoma.
    Whitehead RP; Figlin R; Citron ML; Pfile J; Moldawer N; Patel D; Jones G; Levitt D; Zeffren J
    J Immunother Emphasis Tumor Immunol; 1993 Feb; 13(2):117-21. PubMed ID: 8318496
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Outpatient biochemotherapy with interleukin-2 and interferon alfa-2b in patients with metastatic malignant melanoma: results of two phase II cytokine working group trials.
    Flaherty LE; Atkins M; Sosman J; Weiss G; Clark JI; Margolin K; Dutcher J; Gordon MS; Lotze M; Mier J; Sorokin P; Fisher RI; Appel C; Du W
    J Clin Oncol; 2001 Jul; 19(13):3194-202. PubMed ID: 11432886
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Chemo-/immunotherapy in advanced malignant melanoma: carboplatin and DTIC or cisplatin, dtic, bcnu and tamoxifen followed by immunotherapy with interleukin 2 and interferon alpha-2a].
    Kirchner HH; Atzpodien J; Poliwoda H
    Med Klin (Munich); 1996 Apr; 91 Suppl 3():44-9. PubMed ID: 8692119
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Increased proliferation, cytotoxicity, and gene expression after stimulation of human peripheral blood T lymphocytes through a surface ganglioside (GD3).
    Norihisa Y; McVicar DW; Ghosh P; Houghton AN; Longo DL; Creekmore SP; Blake T; Ortaldo JR; Young HA
    J Immunol; 1994 Jan; 152(2):485-95. PubMed ID: 8283032
    [TBL] [Abstract][Full Text] [Related]  

  • 56. A Phase I/Ib study of folate immune (EC90 vaccine administered with GPI-0100 adjuvant followed by EC17) with interferon-α and interleukin-2 in patients with renal cell carcinoma.
    Amato RJ; Shetty A; Lu Y; Ellis PR; Mohlere V; Carnahan N; Low PS
    J Immunother; 2014 May; 37(4):237-44. PubMed ID: 24714357
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Prospective randomized trial of interferon alfa-2b and interleukin-2 as adjuvant treatment for resected intermediate- and high-risk primary melanoma without clinically detectable node metastasis.
    Hauschild A; Weichenthal M; Balda BR; Becker JC; Wolff HH; Tilgen W; Schulte KW; Ring J; Schadendorf D; Lischner S; Burg G; Dummer R
    J Clin Oncol; 2003 Aug; 21(15):2883-8. PubMed ID: 12885805
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Intensive therapy with cisplatin, interleukin-2 and interferon-alpha-2a in patients with metastatic melanoma. A phase II Study.
    Sznol M; Steis RG; Smith JW; Janik JE; Sharfman WH; Urba WJ; Fenton RG; Creekmore SP; Beveridge J; Longo DL
    Online J Curr Clin Trials; 1992 Jul; Doc No 9():[3841 words; 32 paragraphs]. PubMed ID: 1343617
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Combination therapy with interferon-gamma and interleukin-2 for the treatment of metastatic melanoma.
    Kim CJ; Taubenberger JK; Simonis TB; White DE; Rosenberg SA; Marincola FM
    J Immunother Emphasis Tumor Immunol; 1996 Jan; 19(1):50-8. PubMed ID: 8859724
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Biological study of R24 mouse monoclonal antibody in patients undergoing thoracotomy for pulmonary metastases from soft tissue sarcoma.
    Casper ES; Cordon-Cardo C; Houghton AN; Steffens TA; McCormack P; Magill GB; Hajdu SI; Brennan MF
    Cancer Invest; 1994; 12(1):20-5. PubMed ID: 8281462
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.